Article Contents ::
- 1 The Brand Name DORTAS Has Generic Salt :: DORZOLAMIDE
- 2 DORTAS Is From Company Intas Priced :: Rs. 180
- 3 DORTAS have DORZOLAMIDE is comes under Sub class Anti Glaucoma Drugs of Main Class Ocular
- 4 Main Medicine Class:: Ocular Sub Medicine Class :: Anti Glaucoma Drugs
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DORTAS Has Generic Salt :: DORZOLAMIDE
DORTAS Is From Company Intas Priced :: Rs. 180
DORTAS have DORZOLAMIDE is comes under Sub class Anti Glaucoma Drugs of Main Class Ocular
Main Medicine Class:: Ocular Sub Medicine Class :: Anti Glaucoma Drugs
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| DORZOLAMIDE | EYE DPS | Rs. 180 | 3ML |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 3ML |
| DORTAS | Intas | 2% | 3ML | Rs. 180 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Intas :: DORTAS | DORZOLAMIDE | Ocular | Anti Glaucoma Drugs |
Indications for Drugs ::
Open-angle glaucoma, Ocular hypertension
Drug Dose ::
Adult: As soln containing timolol 0.5% and dorzolamide 2%: Instill 1 drop twice daily. Renal impairment: CrCl (ml/min) <30 Not recommended. Contraindication ::
Hypersensitivity to any of the components or sulphonamide. History or current bronchial asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock, CrClr <30 ml/min and hyperchloraemic acidosis. Drug Precautions ::
Hepatic impairment, mild to moderate renal impairment, children <2 yr. Avoid use in pregnancy and lactation. Prinzmetal's angina, cardiac disease, hypotension, myasthenia gravis, history of renal calculi, history of intra-ocular surgery, pre-existing chronic corneal defects. May worsen severe peripheral and central circulatory disorders. May mask symptoms of hypoglycaemia and hyperthyroidism. Withdraw gradually, especially in patients with coronary heart disease. Discontinue treatment at the first signs or symptoms of cardiac failure. Contact lenses to be removed before eyedrop application and wait at least 15 minutes before reinsertion. Apply other eyedrops 10 minutes apart. May affect ability to drive or operate machinery as it may cause blurred vision. Drug Side Effects ::
Ocular irritation, burning, stinging, itching and tearing; conjunctival inj, eyelid inflammation or irritation, corneal erosion, blurred vision, headache, sinusitis, taste perversion, nausea, fatigue. Potentially Fatal: Cardiac failure, bronchospasm.
Pregnancy category ::
3
Drug Mode of Action ::
Timolol maleate, a nonselective ?-adrenergic blocker, reduces aqueous humor formation. Dorzolamide, a carbonic anhydrase inhibitor, has actions similar to acetazolamide. By inhibiting carbonic anhydrase in the ciliary processes of the eye, dorzolamide decreases aqueous humor secretion. Used together, there is additional intraocular pressure reduction compared to using either component alone, but the reduction is not as much as concomitant admin of dorzolamide tid and timolol bid.
Drug Interactions ::
Additive hypotension and bradycardia with oral calcium channel blockers, catecholamine-depleting drugs or ?-blockers, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Additive systemic side effects with oral carbonic anhydrase or ?-blockers; avoid concurrent use. Additive systemic ?-blockade with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.
